Captopril
- Generic Name
- Captopril
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H15NO3S
- CAS Number
- 62571-86-2
- Unique Ingredient Identifier
- 9G64RSX1XD
- Background
Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
- Indication
For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
- Associated Conditions
- Aldosteronism, Anatomic renal artery stenosis, Congestive Heart Failure (CHF), Diabetic Nephropathy, Heart Failure, Hypertension, Hypertensive crisis, Non-STEMI Acute Coronary Syndrome, Raynaud's Phenomenon, Ejection fraction of 40% or less Left ventricular dysfunction
- Associated Therapies
- -
Rapid Versus Prolonged Inpatient Up-Titration of Captopril
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2008-08-27
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 50
- Registration Number
- NCT00742040
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy
- Conditions
- Diabetic Nephropathy
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT00663949
- Locations
- 🇮🇷
Shiraz University of Medical Sciences ,Nemazee and Faghihi Hospital, Shiraz, Fars, Iran, Islamic Republic of
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00660309
- Locations
- 🇺🇸
Novartis Investigator Site, Boston, Massachusetts, United States
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
- Conditions
- Heart FailureVentricular Dysfunction, Left
- Interventions
- Drug: CaptoprilDrug: EnalaprilDrug: LisinoprilDrug: RamiprilDrug: TrandolaprilDrug: BisoprololDrug: CarvedilolDrug: Metoprolol succinateDrug: CandesartanDrug: ValsartanDrug: EplerenoneDrug: SpironolactoneDrug: DiureticsDrug: HF treatment according to Swedish guidelinesProcedure: Blood samplesProcedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT00391846
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDrug: ClonidineDrug: Nitroglycerin transdermalDrug: Dipyridamole/ Aspirin (Aggrenox)Drug: Desmopressin (DDAVP)Drug: SildenafilDrug: NifedipineDrug: HydralazineDrug: HydrochlorothiazideDrug: BosentanDrug: DiltiazemDrug: EplerenoneDrug: guanfacineDietary Supplement: L-arginineDrug: captoprilDrug: carbidopaDrug: losartanDrug: metoprolol tartrateDrug: nebivolol hydrochlorideDrug: prazosin hydrochlorideDrug: tamsulosin hydrochlorideOther: Head-up tilt.Drug: aliskirenOther: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00086723
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
- Conditions
- Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 35
- Registration Number
- NCT00004230
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy
- Conditions
- Lung CancerPulmonary ComplicationsRadiation Fibrosis
- Interventions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 81
- Registration Number
- NCT00077064
- Locations
- 🇺🇸
Mount Carmel Health - West Hospital, Columbus, Ohio, United States
🇺🇸Doctors Hospital at Ohio Health, Columbus, Ohio, United States
🇺🇸Great Lakes Cancer Institute at McLaren Regional Medical Center, Flint, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.